Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 4Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

Cyclophosphamide 18fludarabine phosphate 12pembrolizumab 11Nivolumab 11Brentuximab Vedotin 11Mycophenolic Acid 10Doxorubicin 10fludarabine 9Dacarbazine 9Whole-Body Irradiation 8Etoposide 8Vinblastine 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Filgrastim 7Cyclosporine 7Granulocyte Colony-Stimulating Factor 6Sirolimus 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Gemcitabine 5Busulfan 5Tacrolimus 4pegfilgrastim 3Vinorelbine 3Stem Cell Transplantation 3Rituximab 3Radiation 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × decitabine and cedazuridine drug combination × 90 days × Clear all
NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡